Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose insulin for prevention of excessive cutaneous scarring after bilateral breast surgery
2010-022290-34Phase 2Completed
- Sponsor
- Pharmecosse
- Start
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of human insulin in pathological scarring (PS) and surgical scar (2 arms), sponsored by Pharmecosse. Primary endpoint: Severity of scar formation. Started Oct 2010; status: completed.
02
Drugs
human insulin
03
Conditions
pathological scarring (PS)surgical scar
Beyond the preview
Go deeper on 2010-022290-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022290-34.